Published in J Pathol on January 01, 1999
Acetylation is indispensable for p53 activation. Cell (2008) 5.70
p53 ubiquitination: Mdm2 and beyond. Mol Cell (2006) 5.57
Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev (2000) 5.04
Oscillations and variability in the p53 system. Mol Syst Biol (2006) 4.59
PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A (2003) 4.46
Mutant p53: one name, many proteins. Genes Dev (2012) 4.33
"Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J (2002) 4.17
Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A (2003) 4.06
ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev (2001) 4.06
Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci U S A (2000) 3.74
Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J (2002) 3.45
p53 polymorphisms: cancer implications. Nat Rev Cancer (2009) 3.33
Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol (2004) 3.31
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 3.17
Identification and classification of p53-regulated genes. Proc Natl Acad Sci U S A (1999) 3.07
Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci U S A (2004) 3.06
CDK8 is a stimulus-specific positive coregulator of p53 target genes. Mol Cell (2007) 2.88
Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol Cell Biol (2004) 2.80
Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell (2008) 2.71
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A (2009) 2.61
P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A (2010) 2.49
Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med (2001) 2.47
MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol (2003) 2.45
p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J (2000) 2.38
p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J (2000) 2.38
HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53. Genes Dev (2007) 2.32
Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurg Rev (2003) 2.32
A plausible model for the digital response of p53 to DNA damage. Proc Natl Acad Sci U S A (2005) 2.32
ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J (2005) 2.29
The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci U S A (2003) 2.29
Functional architecture in the cell nucleus. Biochem J (2001) 2.28
The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J (2006) 2.21
Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci U S A (2005) 2.14
Modeling cancer progression via pathway dependencies. PLoS Comput Biol (2008) 2.12
Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol (2006) 2.02
H3K4me3 interactions with TAF3 regulate preinitiation complex assembly and selective gene activation. Cell (2013) 2.00
Trim24 targets endogenous p53 for degradation. Proc Natl Acad Sci U S A (2009) 2.00
The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell (2011) 1.92
Role of Stat3 in regulating p53 expression and function. Mol Cell Biol (2005) 1.91
Cancer predisposition and hematopoietic failure in Rad50(S/S) mice. Genes Dev (2002) 1.87
MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. EMBO J (2005) 1.85
Having it both ways: transcription factors that bind DNA and RNA. Nucleic Acids Res (2002) 1.84
Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells. Mol Cell Biol (2003) 1.83
WISP-1 attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase. Genes Dev (2002) 1.80
Phosphorylation of murine p53 at ser-18 regulates the p53 responses to DNA damage. Proc Natl Acad Sci U S A (2000) 1.80
MDMX regulation of p53 response to ribosomal stress. EMBO J (2006) 1.77
p19ARF targets certain E2F species for degradation. Proc Natl Acad Sci U S A (2001) 1.75
SnapShot: p53 posttranslational modifications. Cell (2008) 1.75
Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A (2002) 1.72
Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J (2001) 1.69
Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3. EMBO J (2006) 1.67
Mutation of mouse p53 Ser23 and the response to DNA damage. Mol Cell Biol (2002) 1.65
Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci U S A (2003) 1.63
The phenotype of MDM2 auto-degradation after DNA damage is due to epitope masking by phosphorylation. Cell Cycle (2011) 1.62
Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci U S A (2003) 1.60
ATM activates p53 by regulating MDM2 oligomerization and E3 processivity. EMBO J (2009) 1.56
p53 Stabilization and accumulation induced by human vaccinia-related kinase 1. Mol Cell Biol (2004) 1.56
Deconstructing PML-induced premature senescence. EMBO J (2002) 1.56
A role for p53 in base excision repair. EMBO J (2001) 1.56
Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol (2005) 1.54
Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol Cell Biol (2001) 1.54
Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. Proc Natl Acad Sci U S A (2000) 1.54
DNA damage induces MDMX nuclear translocation by p53-dependent and -independent mechanisms. Mol Cell Biol (2002) 1.53
p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc Natl Acad Sci U S A (2004) 1.53
Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage. Mol Cell Biol (2000) 1.46
The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms. J Virol (2002) 1.45
Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol (2004) 1.44
Emerging insights into the molecular pathogenesis of uveal melanoma. Future Oncol (2008) 1.44
A single-molecule characterization of p53 search on DNA. Proc Natl Acad Sci U S A (2010) 1.43
ZBP-89 promotes growth arrest through stabilization of p53. Mol Cell Biol (2001) 1.43
Regulation of p53-MDMX interaction by casein kinase 1 alpha. Mol Cell Biol (2005) 1.41
Proteomic studies reveal coordinated changes in T-cell expression patterns upon infection with human immunodeficiency virus type 1. J Virol (2008) 1.40
Pathologies associated with the p53 response. Cold Spring Harb Perspect Biol (2010) 1.40
Mutation analysis of the CHK2 gene in families with hereditary breast cancer. Br J Cancer (2001) 1.39
Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J (2000) 1.38
Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. Mol Cell Biol (2002) 1.38
DEC1, a basic helix-loop-helix transcription factor and a novel target gene of the p53 family, mediates p53-dependent premature senescence. J Biol Chem (2007) 1.37
Biological contexts for DNA charge transport chemistry. Curr Opin Chem Biol (2008) 1.37
p73alpha regulation by Chk1 in response to DNA damage. Mol Cell Biol (2003) 1.36
DNA polymerase eta, the product of the xeroderma pigmentosum variant gene and a target of p53, modulates the DNA damage checkpoint and p53 activation. Mol Cell Biol (2006) 1.35
A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem Biol (2011) 1.35
Single nucleotide polymorphism seeking long term association with complex disease. Nucleic Acids Res (2002) 1.33
Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX. J Biol Chem (2009) 1.31
Increased DNA damage sensitivity and apoptosis in cells lacking the Snf5/Ini1 subunit of the SWI/SNF chromatin remodeling complex. Mol Cell Biol (2006) 1.30
p53 mediates the negative regulation of MDM2 by orphan receptor TR3. EMBO J (2006) 1.30
Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol (2000) 1.29
Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer (2007) 1.29
mtCLIC/CLIC4, an organellular chloride channel protein, is increased by DNA damage and participates in the apoptotic response to p53. Mol Cell Biol (2002) 1.28
Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol (2001) 1.27
p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop. Mol Cell Biol (2006) 1.26
Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-kappaB pathway and is dependent on p53 phosphorylation. Mol Cell Biol (2000) 1.26
The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes. Mol Cell Biol (2006) 1.24
Inhibition of p53 tumor suppressor by viral interferon regulatory factor. J Virol (2001) 1.24
A global suppressor motif for p53 cancer mutants. Proc Natl Acad Sci U S A (2004) 1.24
APAF1 is a key transcriptional target for p53 in the regulation of neuronal cell death. J Cell Biol (2001) 1.24
Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc (2014) 1.23
Impaired regulation of tumor suppressor p53 caused by mutations in the xeroderma pigmentosum DDB2 gene: mutual regulatory interactions between p48(DDB2) and p53. Mol Cell Biol (2003) 1.22
The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters. BMC Cancer (2009) 1.20
p53-Dependent p21 mRNA elongation is impaired when DNA replication is stalled. Mol Cell Biol (2006) 1.20
The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res (1994) 3.28
A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol (1991) 2.71
Lassa fever in the United States. Investigation of a case and new guidelines for management. N Engl J Med (1990) 2.57
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer (1991) 2.52
Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology (1993) 2.52
p53 in tumour pathology: can we trust immunohistochemistry?--Revisited! J Pathol (1994) 2.41
The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S+G2+M phase fraction (flow cytometric analysis) and prognosis. Histopathology (1991) 2.32
Epidermal growth factor (EGF/URO) induces expression of regulatory peptides in damaged human gastrointestinal tissues. J Pathol (1990) 2.29
In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol (1993) 2.07
p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet (1991) 1.95
The prohibitin family of mitochondrial proteins regulate replicative lifespan. Curr Biol (1997) 1.86
High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A (1997) 1.81
Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol (1987) 1.80
Primary malignant lymphoma of the colon and rectum. A histopathological and immunohistochemical analysis of 45 cases with clinicopathological correlations. Histopathology (1988) 1.76
Do we really need a higher necropsy rate? Lancet (1999) 1.71
Gadd45 is a nuclear cell cycle regulated protein which interacts with p21Cip1. Oncogene (1995) 1.62
Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol (1991) 1.58
Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci (1995) 1.57
Mammalian prohibitin proteins respond to mitochondrial stress and decrease during cellular senescence. Exp Cell Res (2001) 1.57
The complexities of proliferating cell nuclear antigen. Histopathology (1992) 1.57
Endocrine cells of the human gastrointestinal tract have no proliferative capacity. Histochem J (1995) 1.49
The epidermal growth factor receptor in human pancreatic cancer. J Pathol (1992) 1.47
Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol (1991) 1.46
Koch's postulates revisited. J Pathol (1991) 1.46
The p53 response to ionising radiation in adult and developing murine tissues. Oncogene (1996) 1.46
Ki67--structure, function, and new antibodies. J Pathol (1992) 1.45
APC expression in normal human tissues. J Pathol (1997) 1.44
Comparison of manual data coding errors in two hospitals. J Clin Pathol (1986) 1.42
Sensitive enzyme-linked immunosorbent assay for detection of Clostridium botulinum neurotoxins A, B, and E using signal amplification via enzyme-linked coagulation assay. J Clin Microbiol (1993) 1.41
The relevance of antibody concentration to the immunohistological quantification of cell proliferation-associated antigens. Histopathology (1993) 1.40
Identification of the antigen recognized by the monoclonal antibody BU31 as lamins A and C. J Pathol (1996) 1.38
The p53 tumour suppressor gene. Br J Surg (1998) 1.37
Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology (1992) 1.33
New marker of B lymphocytes, MB2: comparison with other lymphocyte subset markers active in conventionally processed tissue sections. J Clin Pathol (1987) 1.30
Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. Gastroenterology (1992) 1.30
Expression of the 'dead box' RNA helicase p68 is developmentally and growth regulated and correlates with organ differentiation/maturation in the fetus. J Pathol (1998) 1.23
Proliferative activity of cells in the synovium as demonstrated by a monoclonal antibody, Ki67. Rheumatol Int (1987) 1.22
Characterization of the expression pattern of p63 alpha and delta Np63 alpha in benign and malignant oral epithelial lesions. Int J Cancer (2000) 1.21
Do septins have a role in cancer? Br J Cancer (2005) 1.20
Angiotropic large cell lymphoma (ALCL): morphological, immunohistochemical and genotypic studies with analysis of previous reports. Hematol Oncol (1989) 1.18
Rapid technique of DNA-DNA in situ hybridisation on formalin fixed tissue sections using microwave irradiation. J Clin Pathol (1987) 1.17
Haemangiopericytomas: the prognostic value of immunohistochemical staining with a monoclonal antibody to proliferating cell nuclear antigen (PCNA). Histopathology (1991) 1.17
The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. J Oral Pathol Med (2000) 1.16
MDM2--arbiter of p53's destruction. Trends Biochem Sci (1997) 1.15
Regulation of the CYP1A1 promoter in transgenic mice: an exquisitely sensitive on-off system for cell specific gene regulation. J Cell Sci (1996) 1.14
Characterization of a panel of novel anti-p21Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues. Am J Pathol (1996) 1.12
Primary malignant lymphoma of the large intestine complicating chronic inflammatory bowel disease. Histopathology (1989) 1.11
Enteroendocrine cell hyperplasia, carcinoid tumours and adenocarcinoma in long-standing ulcerative colitis. Histopathology (1986) 1.10
Immunolocalization of fibroblast growth factor receptor 1 and its ligands in human tissues. Lab Invest (1993) 1.10
Do aggressive subclones within primary colorectal cancer give rise to liver metastases? Int J Colorectal Dis (1989) 1.10
Enzyme-linked immunosorbent assay and enzyme-linked coagulation assay for detection of Clostridium botulinum neurotoxins A, B, and E and solution-phase complexes with dual-label antibodies. J Clin Microbiol (1994) 1.08
Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res (1994) 1.08
Demonstration of DNA damage/repair in individual cells using in situ end labelling: association of p53 with sites of DNA damage. J Pathol (1995) 1.07
p53--integrating the complexity. J Pathol (1996) 1.06
The location of pKi67 in the outer dense fibrillary compartment of the nucleolus points to a role in ribosome biogenesis during the cell division cycle. J Pathol (2000) 1.05
Antigen retrieval by microwave irradiation lowers immunohistological detection thresholds. Histopathology (1993) 1.02
Epithelial tumors metastatic to the uterine cervix. A study of 33 cases and review of the literature. Cancer (1986) 1.01
Proliferative compartment deregulation in the non-neoplastic colonic epithelium of familial adenomatous polyposis. Gut (1995) 1.01
Antibodies to T cell antigen receptor beta chain families detect monoclonal T cell proliferation. Lancet (1986) 1.00
Acetone/periodate-lysine-paraformaldehyde (PLP) fixation and improved morphology of cryostat sections for immunohistochemistry. Histopathology (1987) 0.94
Expression of basic and acidic fibroblast growth factors and their receptor in normal and atherosclerotic human arteries. Cardiovasc Res (1993) 0.93
Transcriptional activation of tyrosinase and TRP-1 by p53 links UV irradiation to the protective tanning response. J Pathol (2000) 0.91
Ki67: from antibody to molecule to understanding? Clin Mol Pathol (1995) 0.90
The role of the p53 protein in the apoptotic response. Philos Trans R Soc Lond B Biol Sci (1994) 0.90
p53 expression is common in malignant mesothelioma. Histopathology (1992) 0.90
The biochemical characterization of the DNA binding activity of pKi67. J Pathol (2000) 0.88
Control of differentiation in a rectal adenocarcinoma cell line: the role of diffusable and cell-associated factors. J Pathol (1991) 0.88
Biochemical characterization of pKi67 with the identification of a mitotic-specific form associated with hyperphosphorylation and altered DNA binding. Exp Cell Res (1999) 0.87
Fen1 expression: a novel marker for cell proliferation. J Pathol (1998) 0.87
A nude mouse xenograft model of fetal intestine development and differentiation. Development (1992) 0.86
The Trp53 pathway is induced in vivo by low doses of gamma radiation. Radiat Res (2001) 0.85
Classification of primary gut lymphomas. Lancet (1988) 0.85
Extraction of DNA from small sections of frozen tissue with simultaneous histological examination. J Clin Pathol (1988) 0.85
Does the p53 up-regulated Gadd45 protein have a role in excision repair? Science (1995) 0.84
A functional model of adult human prostate epithelium. The role of androgens and stroma in architectural organisation and the maintenance of differentiated secretory function. J Cell Sci (1992) 0.83
Why is p53 protein stabilized in neoplasia? Some answers but many more questions? J Pathol (1998) 0.83
Malignant lymphoma with eosinophilia of the gastrointestinal tract. Histopathology (1987) 0.83
Growth factors and oncogenes in pancreatic cancer. Baillieres Clin Gastroenterol (1990) 0.83
Simultaneous presentation of T- and B-cell malignant lymphoma with bcl-2 gene involvement. Blood (1989) 0.82
Proliferating cell nuclear antigen immunolocalization in gastro-intestinal epithelia. Digestion (1991) 0.82
The immunocytochemical detection of p53 protein in cytological specimens: technical considerations. Cytopathology (1994) 0.82
The association between cell proliferation and apoptosis: studies using the cell cycle-associated proteins Ki67 and DNA polymerase alpha. J Pathol (1996) 0.81
An immunochemical analysis of mdm2 expression in human breast cancer and the identification of a growth-regulated cross-reacting species p170. J Pathol (1998) 0.81
The yeast two-hybrid system for identifying protein-protein interactions. J Pathol (2003) 0.80
Management of localized non-Hodgkin's lymphoma: the experience at St. Bartholomew's Hospital 1972-1985. Hematol Oncol (1989) 0.79
Tumour diagnosis. Nature (1994) 0.79
The p53 tumour suppressor gene and tumour prognosis: is there a relationship? J Pathol (1995) 0.79
Molecular and cellular themes in inflammation and immunology. J Pathol (2008) 0.79
Overview of the fibroblast growth factor and receptor families: complexity, functional diversity, and implications for future cardiovascular research. Cardiovasc Res (1993) 0.79
Epithelial-mesenchymal interactions can influence the phenotype of carcinoma metastases in the mucosa of the intestine. J Pathol (1990) 0.78
A monoclonal antibody (anti-L-35) which reacts with human osteoclasts and cells of the mononuclear phagocyte system. Br J Exp Pathol (1988) 0.78
The clinical relevance of the p53 tumour suppressor gene. Cytopathology (1994) 0.78
Gadd45 mutations are uncommon in human tumour cell lines. Cell Prolif (2000) 0.78
Expression of the nuclear membrane protein statin in cycling cells. J Pathol (1993) 0.78
The fibroblast growth factor and receptor multigene families. J Pathol (1993) 0.77
Analysis of apoptosis in tissue sections. Methods Mol Biol (2001) 0.77
Modeling the growth of Listeria monocytogenes in cured ready-to-eat processed meat products by manipulation of sodium chloride, sodium diacetate, potassium lactate, and product moisture content. J Food Prot (2002) 0.77
Challenges to improving health risk communication in the 21st century: a discussion. J Natl Cancer Inst Monogr (1999) 0.77
Measuring a cell's response to stress: the p53 pathway. Genome Biol (2000) 0.77
The gut-associated lymphoid tissue and its tumours. Curr Top Pathol (1990) 0.77